Literature DB >> 15945374

Separate-component-stabilization system for protein and DNA production without the use of antibiotics.

Cédric Y Szpirer1, Michel C Milinkovitch.   

Abstract

Plasmid instability is a significant concern in the industrial utilization of microorganisms for protein or DNA production. Here we report on the development of a new and highly effective stabilization system based on the use of the ccd antidote/poison genes. For the first time, we separated the antidote gene from the poison gene: localizing the former in the plasmid and integrating the latter in the bacterial chromosome. We show that this separate-component-stabilization (SCS) strategy: (i) allows for perfect stabilization without the use of antibiotics; (ii) increases three to five times the recombinant protein production levels; and (iii) does not require any specific modification of the protein production process or culture medium. We illustrate that point by using the classical T7 promotor (i.e., used in most expression systems). Finally, we demonstrate that the SCS system increases by five the yield in DNA production, a result especially important for the design and production of gene therapy constructs void of any antibiotic resistance gene.

Mesh:

Substances:

Year:  2005        PMID: 15945374     DOI: 10.2144/05385RR02

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  20 in total

1.  Use of Staby(®) technology for development and production of DNA vaccines free of antibiotic resistance gene.

Authors:  Anca Reschner; Sophie Scohy; Gaëlle Vandermeulen; Marc Daukandt; Céline Jacques; Benjamin Michel; Hans Nauwynck; Florence Xhonneux; Véronique Préat; Alain Vanderplasschen; Cédric Szpirer
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

2.  Identification of Vibrio natriegens uvrA and uvrB genes and analysis of gene regulation using transcriptional reporter plasmids.

Authors:  Keryn L Simons; Susan M Thomas; Peter A Anderson
Journal:  J Microbiol       Date:  2010-11-03       Impact factor: 3.422

Review 3.  New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials.

Authors:  Gaëlle Vandermeulen; Corinne Marie; Daniel Scherman; Véronique Préat
Journal:  Mol Ther       Date:  2011-08-30       Impact factor: 11.454

Review 4.  Antibiotic-free selection in biotherapeutics: now and forever.

Authors:  Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Pathogens       Date:  2015-04-03

Review 5.  Biology and evolution of bacterial toxin-antitoxin systems.

Authors:  Dukas Jurėnas; Nathan Fraikin; Frédéric Goormaghtigh; Laurence Van Melderen
Journal:  Nat Rev Microbiol       Date:  2022-01-02       Impact factor: 60.633

Review 6.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

7.  Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system.

Authors:  Jeremy Luke; Aaron E Carnes; Clague P Hodgson; James A Williams
Journal:  Vaccine       Date:  2009-06-24       Impact factor: 3.641

8.  Efficient strategies to enhance plasmid stability for fermentation of recombinant Escherichia coli harboring tyrosine phenol lyase.

Authors:  Xiao-Ling Tang; Wen-Ye Hu; Zhi-Chao Wang; Ren-Chao Zheng; Yu-Guo Zheng
Journal:  Biotechnol Lett       Date:  2021-04-08       Impact factor: 2.461

9.  Optimization of medium composition to increase the expression of recombinant human interferon-β using the Plackett-Burman and central composite design in E. coli SE1.

Authors:  Dharam Pal; Gopal Patel; Prakashkumar Dobariya; Shivraj Hariram Nile; Abhay H Pande; Uttam Chand Banerjee
Journal:  3 Biotech       Date:  2021-04-19       Impact factor: 2.406

10.  Stable expression plasmids for Streptomyces based on a toxin-antitoxin system.

Authors:  Laura Sevillano; Margarita Díaz; Ramón I Santamaría
Journal:  Microb Cell Fact       Date:  2013-04-25       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.